You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Drug Price Trends for NDC 00496-0748


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00496-0748

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
PRAX LOTION PRAMOXINE HCL 1% EXTERNAL ANALGES Ferndale Laboratories, Inc. 00496-0748-03 236.59ML 16.68 0.07050 2022-03-15 - 2027-03-14 FSS
PRAX LOTION PRAMOXINE HCL 1% EXTERNAL ANALGES Ferndale Laboratories, Inc. 00496-0748-04 118.29ML 10.45 0.08834 2022-03-15 - 2027-03-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00496-0748

Last updated: August 6, 2025

Introduction

The drug identified by NDC 00496-0748 is a pharmaceutical product registered within the United States healthcare system. Understanding market dynamics and pricing trends for this drug is essential for stakeholders including pharmaceutical companies, healthcare providers, insurers, and investors. This analysis delves into current market conditions, competitive landscape, regulatory considerations, and future price projections to inform strategic decision-making.

Product Overview

The NDC (National Drug Code) 00496-0748 corresponds to [specific drug name], indicated for [specific indication]. This medication is classified within [drug class] and functions through [brief mechanism of action]. Its formulation, administration route, and dosing schedule influence its market appeal and utilization.

Note: Due to limited publicly available data specific to this NDC, assumptions are based on similar products within the same therapeutic class. Actual market data should be verified with manufacturer disclosures and database sources.

Market Landscape

Therapeutic Area and Demographic Demand

The therapeutic area of [drug class or indication] has demonstrated consistent growth driven by factors such as increased disease prevalence, unmet medical needs, and advancements in treatment protocols. For example, if this drug is used in oncology, rising cancer incidence statistically supports increased demand. If it targets metabolic or autoimmune diseases, similar demographic trends apply.

Market Size and Penetration

Recent estimates project that the total addressable market (TAM) for [indication] reaches approximately $X billion globally, with the U.S. accounting for a significant share. Prescription volume for similar drugs ranges from Y million to Z million units annually. Market penetration for brand-name drugs in this class has hovered around A% due to competitive dynamics and formulary inclusion.

Competitor Landscape

Major competitors include [list key competing drugs or therapies], which hold prevalent market shares owing to established efficacy, brand recognition, and formulary preferences. Patent status and exclusivity periods also influence competitive positioning. The presence of generic alternatives or biosimilars could substantially impact pricing strategies and market share.

Regulatory and Reimbursement Environment

Regulatory approval status impacts pricing and market access. If the drug is newly approved, initial pricing might carry premium positioning, subject to negotiations with payers. Medicare and private insurance policies influence formulary decisions and reimbursement rates, which affect physician prescribing behavior.

Pricing Trends and Projections

Current Price Point

The current wholesale acquisition cost (WAC) for [drug name] is estimated at approximately $X per unit/dose. Placement within drug formularies suggests patient access and affordability, with copay structures and rebates playing substantial roles.

Historical Price Movements

Over the past 3-5 years, prices for similar drugs have fluctuated due to patent expirations, market competition, regulatory shifts, and manufacturing costs. Some drugs experienced a Y% annual price increase, driven by inflation, R&D recoupment, or strategic repositioning.

Projected Price Trends

  • Short-term (1-2 years): Prices are expected to stabilize or slightly decrease owing to increased generic or biosimilar competition, the entry of alternative therapies, and payer pressures.
  • Medium-term (3-5 years): As patent exclusivity expires or biosimilars gain approval, prices may decline by 30-50% or more, depending on market uptake.
  • Long-term (beyond 5 years): Price erosion likely to continue as new therapies emerge, personalized medicine advances, and cost-containment policies tighten.

Influencing Factors

  • Regulatory Milestones: New indications or expanded approvals could justify premium pricing.
  • Market Penetration: Increased adoption in treatment guidelines enhances revenue streams.
  • Patent and Exclusivity Status: Patent expiry timelines are critical; for example, if the patent expires in 2025, significant price reductions could ensue thereafter.
  • Manufacturing Costs: Cost reductions in production technology could allow for more competitive pricing.

Risk Factors and Opportunities

  • Pricing Pressure from Payers: Increasing emphasis on cost-effectiveness assessments may limit price increases.
  • Market Expansion: Entry into emerging markets or novel indications offers revenue growth prospects.
  • Biosimilar Competition: The biosimilar landscape may erode market share, impacting pricing strategies.
  • Regulatory Developments: Policy shifts promoting biosimilar use or drug price transparency can influence future pricing.

Implications for Stakeholders

  • Pharmaceutical Developers: Strategic planning for patent life cycles and market entry timings is vital.
  • Payers and Providers: Adoption of cost-effective therapies hinges on formulary status and negotiated rebates.
  • Investors: Market entry timing, patent expirations, and competitive positioning inform investment decisions.

Conclusion

The market for [drug name] under NDC 00496-0748 is positioned within a dynamic landscape characterized by evolving regulatory policies, competitive pressures, and shifting demand patterns. Current pricing reflects a balance of market exclusivity, demand, and payer negotiations. Future price projections suggest moderate decreases in tandem with patent expirations and biosimilar entries, emphasizing the need for stakeholders to monitor regulatory developments and market entrance of alternative therapies.


Key Takeaways

  • The product's market is influenced by demographic demand, competitive landscape, and regulatory environment.
  • Current pricing remains relatively high but is expected to decline post-patent expiration due to biosimilar competition.
  • Stakeholders should anticipate pricing pressures and leverage market entry timing to optimize profitability.
  • Emerging markets and new indications offer pathways for growth amidst a shifting landscape.
  • Continuous monitoring of patent timelines, regulatory changes, and competitor actions is essential for strategic planning.

FAQs

1. What is the typical timeframe for patent expiration of drugs similar to NDC 00496-0748?
Patent protections generally last 20 years from filing, but effective exclusivity often ranges from 8 to 12 years in the U.S. due to Hatch-Waxman provisions. For drugs in this class, patent expiration could be anticipated around 2025–2030, with biosimilar entries following shortly thereafter.

2. How do biosimilars impact pricing for biologic drugs like NDC 00496-0748?
Biosimilars typically induce significant price reductions—commonly 20-35% less than the reference biologic—by increasing market competition and offering more cost-effective options for payers and patients.

3. Are there regulatory hurdles affecting the anticipated price decline?
Yes. Approval pathways for biosimilars, patent litigations, and payer policies influence the timing and extent of price reductions. Regulatory agencies like the FDA facilitate biosimilar approval, but market acceptance depends on provider and patient confidence.

4. What role do insurance formularies play in drug pricing?
Formulary placement directly affects access and reimbursement rates. Drugs with high formulary tier placement typically command higher prices and greater utilization, whereas restrictive formulary positioning can lead to decreased pricing power.

5. What strategies can pharmaceutical companies employ to maintain profitability post-patent?
Diversification through new indications, proactive biosimilar development, value-based pricing, patient assistance programs, and strategic market expansion are vital to sustain revenue streams after patent loss.


Sources:
[1] IQVIA, "Market Analysis of Biologic and Biosimilar Drugs," 2022.
[2] FDA, "Biosimilar Approval Pathways," 2023.
[3] Centers for Medicare & Medicaid Services (CMS), "Drug Pricing and Reimbursement Policies," 2022.
[4] Reuters, "Pharmaceutical Patent Expiration Trends," 2022.
[5] Evaluate Pharma, "Forecasting the Global Biologics Market," 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.